CN1919206A - Vitexin injection and oral administration preparation thereof - Google Patents
Vitexin injection and oral administration preparation thereof Download PDFInfo
- Publication number
- CN1919206A CN1919206A CN 200510094062 CN200510094062A CN1919206A CN 1919206 A CN1919206 A CN 1919206A CN 200510094062 CN200510094062 CN 200510094062 CN 200510094062 A CN200510094062 A CN 200510094062A CN 1919206 A CN1919206 A CN 1919206A
- Authority
- CN
- China
- Prior art keywords
- vitexin
- injection
- oral formulations
- diluent
- cosolvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Vitexin injection or oral administration preparation for treating cardiovascular diseases and process for preparation, wherein each 1000ml of the Vitexin injection comprises Vitexin 0.1-100g, each 1000 dosage units of the oral administration preparation comprises Vitexin 0.1-100g, and medicinal supplementary materials comprises diluent, flow aid, auxiliary solvent, excipient and osmoregulation agent.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of treatment cardiovascular disease medicament, specifically relate to a kind of vitexin injection (little liquid drugs injection, lyophilized injectable powder, glucose injection and sodium chloride injection) and oral formulations (tablet, capsule, drop pill, soft capsule, oral liquid, granule, aerosol), can be used for arteriovenous injection or oral in saying.The every 1000ml of vitexin injection contains vitexin 0.1～100g, and per 1000 the preparation units of oral formulations contain vitexin 0.1～100g.And the application of vitexin preparation in pharmaceutical field that utilizes the inventive method to obtain, the particularly application in preparation control cardiovascular disease medicine.
Background technology
Fructus Crataegi is one of common drug in China's traditional medicine, and long clinical practice history is arranged.Contain abundant flavonoids in the Folium Crataegi, such as vitexin, vitexin rhamnopyranoside, vitexin glycoside etc., they have anticoagulant; coronary artery dilator improves blood supply of cardiac muscle, reduces myocardial oxygen consumption; ischemic heart desease is produced significant protective effect, the clinical coronary heart disease that is mainly used in, angina pectoris; hyperlipemia, cerebral arterial insufficiency, but all be used as medicine with crude extract; purity is not high; composition mixes, and quality is wayward, seriously hinders clinical practice.
Summary of the invention
The objective of the invention is in order to overcome the prior art deficiency, extraction, purification obtain single active compound vitexin from Folium Crataegi.Thereby a kind of principal agent purity height, safe and reliable, stay-in-grade vitexin injection (little liquid drugs injection, lyophilized injectable powder, glucose injection and sodium chloride injection) and oral formulations (tablet, capsule, drop pill, soft capsule, oral liquid, granule, aerosol) are provided, can be used for arteriovenous injection or oral.The every 1000ml of vitexin injection contains vitexin 0.1～100g, and per 1000 the preparation units of oral formulations contain vitexin 0.1～100g.Animal experiment proof vitexin 4,2,1mgkg
-1, can increase dog coronary artery and aortal blood flow, increase per minute 100 gram myocardial flow and cardiac output; Improve SI and cardiac index; Reduce left indoor pressure, total peripheral vascular resistance and coronary resistance; Cause on dog and the Acute Myocardial Ischemia in Rats damage model vitexin 4,2,1mgkg at coronary ligation
-1Can significantly reduce the ischemia scope and the infarction size of dog cardiac muscle, vitexin 6,3,1.5mgkg
-1Can significantly reduce the infarction size of ischemia rat heart muscle, significantly suppress LDH simultaneously and from the damaged myocardium cell, spill; On blood stasis disease rat model, vitexin 6,3,1.5mgkg
-1Can reduce the plasma viscosity value, increase erythrocyte deformability; On rat carotid artery-external jugular vein bypass model, vitexin 6,3mgkg
-1Can obviously alleviate the dry weight of thrombosis, thereby suppress thrombosis.In addition, vitexin can improve obviously also that the unusual ECG of rats with myocardial ischemia changes due to the sc Iso, reduces myocardium water content, improves the hypoxia-bearing capability of mouse cardiac muscle.Above result of study shows that vitexin has good function of resisting myocardial ischemia, and its effect may be with the blood flow that increases arteria coronaria and cardiac muscle, reduce that blood vessel be penetrated the blood resistance, reduces plasma viscosity, improves the RBC deformability, to suppress thrombosis etc. relevant.
Vitexin preparation safety of the present invention is effective, quality controllable, stable, has very high using value clinically, is a kind of medicine of effective treatment cardiovascular disease.
The specific embodiment
Further introduce the present invention below by embodiment.
The little liquid drugs injection of embodiment 1:()
Component:
Vitexin 3g
Propylene glycol 150g
0.1mol/L NaOH 100ml
Add the injection water to 1000ml
Preparation technology:
Get NaOH and the propylene glycol that vitexin adds 0.1mol/L and make dissolving, add to the full amount of water for injection again, add the needle-use activated carbon decolouring, filter, fill, sterilization, promptly.Wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 2:(freeze-dried powder)
Component:
Vitexin 10g
Mannose 100g
0.1mol/L NaOH 200ml
Make to 1000
Preparation technology:
Get NaOH and the mannitol that vitexin adds 0.1mol/L and make dissolving, add to the full amount of water for injection again, add the needle-use activated carbon decolouring, filter, fill, lyophilization, promptly.Wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 3:(sodium chloride transfusion 100ml/ bottle)
Component:
Vitexin 0.2g
0.1mol/L NaOH 100ml
Sodium chloride 9g
Add the injection water to 1000ml
Preparation technology:
Get the NaOH that vitexin adds 0.1molmol/L and make dissolving, add sodium chloride and water for injection again, add the needle-use activated carbon decolouring, filter to full dose, packing, sterilization, promptly.Wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 4:(glucose injection 100ml/ bottle)
Component:
Vitexin 0.2g
0.1mol/L NaOH 20ml
Glucose 50g
Add the injection water to 1000ml
Preparation technology:
Get the NaOH that vitexin adds 0.1mol/L and make dissolving, add glucose and water for injection again, add the needle-use activated carbon decolouring, filter to full dose, packing, sterilization, promptly.Wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 5 vitexin capsules prescription
Vitexin 10g
Microcrystalline Cellulose 200g
Pulvis Talci 1.4%
3% polyvidone alcoholic solution is an amount of
Said components adopts conventional capsule preparation technology, gets vitexin and microcrystalline Cellulose mix homogeneously, adds 3% polyvidone alcoholic solution system soft material, crosses 18 mesh sieve system granules, and packing is made 1000 then.Wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 6 vitexin tablet formulations
Vitexin 10g
Microcrystalline Cellulose 200g
Pulvis Talci 1.4%
3% polyvidone alcoholic solution is an amount of
Said components adopts conventional capsule preparation technology, get vitexin and microcrystalline Cellulose mix homogeneously, add 3% polyvidone alcoholic solution system soft material, cross 18 mesh sieve system granules, 60 ℃ of dryings 30～45 minutes, granulate, add Pulvis Talci, mixing, tabletting is made 1000 then, and wherein vitexin content should be 90%～110% of labelled amount.
Embodiment 7 vitexin pill prescriptions
Vitexin 5g
PEG400 200g
PEG6000 600g
Said components adopts conventional drop pill preparation technology, gets PEG400 and PEG6000 and adds molten, the mix homogeneously of thermal capacitance, adds vitexin and stirs evenly, and drips and makes 1000 balls, and wherein vitexin content should be 90%～110% of labelled amount.
Claims (6)
1, a kind of vitexin injection (little liquid drugs injection, lyophilized injectable powder, glucose injection and sodium chloride injection) and oral formulations (tablet, capsule, drop pill, soft capsule, oral liquid, granule, aerosol), it is characterized in that containing in every 1000ml medicinal liquid active ingredient vitexin 0.1～100g, per 1000 the preparation units of oral formulations contain vitexin 0.1～100g, and being equipped with the pharmaceutic adjuvant composition, pharmaceutic adjuvant comprises diluent, fluidizer, cosolvent, osmotic pressure regulator.
2, vitexin injection according to claim 1 is characterized in that adopting freeze-drying method, makes the injection vitexin.Every contains vitexin 1～100mg, mannose 0.1～10g.
3, vitexin injection according to claim 1 is characterized in that cosolvent, diluent adopt one or more in propylene glycol, sodium hydroxide test solution, glycerol, Polyethylene Glycol, benzyl benzoate, the dimethyl acetylamide.Osmotic pressure regulator is with sodium chloride or glucose.
4, vitexin oral formulations according to claim 1 is characterized in that cosolvent, diluent, fluidizer adopt starch, dextrin, magnesium stearate, microcrystalline Cellulose, Pulvis Talci, PEG400, PEG6000 etc.
5, vitexin injection according to claim 1 and oral formulations is characterized in that the ischemic hypoxia myocardial damage is had good protective action.Main blood flow by increase arteria coronaria and cardiac muscle reduces blood vessel and penetrates the blood resistance, reduces plasma viscosity, and raising RBC deformability suppresses thrombosis, and the ischemic hypoxia myocardial damage is had good protective action.
6, according to described vitexin injection of claim 5 and oral formulations, it is characterized in that to the treatment cardiovascular disease as: coronary heart disease, angina pectoris, myocardial infarction etc. have certain therapeutical effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510094062 CN1919206A (en) | 2005-08-25 | 2005-08-25 | Vitexin injection and oral administration preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510094062 CN1919206A (en) | 2005-08-25 | 2005-08-25 | Vitexin injection and oral administration preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1919206A true CN1919206A (en) | 2007-02-28 |
Family
ID=37777143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510094062 Pending CN1919206A (en) | 2005-08-25 | 2005-08-25 | Vitexin injection and oral administration preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1919206A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054849A (en) * | 2012-12-21 | 2013-04-24 | 合肥七星医药科技有限公司 | Composition for treating cardiovascnlar and cerebrovascular diseases and preparation method thereof and test method thereof |
| CN105232523A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Natural drug combination for preventing and treating cardiovascular diseases and application thereof |
| CN113264926A (en) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | Co-crystal of vitexin and reserpine and preparation method thereof |
-
2005
- 2005-08-25 CN CN 200510094062 patent/CN1919206A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054849A (en) * | 2012-12-21 | 2013-04-24 | 合肥七星医药科技有限公司 | Composition for treating cardiovascnlar and cerebrovascular diseases and preparation method thereof and test method thereof |
| CN106727498A (en) * | 2012-12-21 | 2017-05-31 | 合肥七星医药科技有限公司 | Treat the composition and its preparation and the method for inspection of cardiovascular and cerebrovascular disease |
| CN105232523A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Natural drug combination for preventing and treating cardiovascular diseases and application thereof |
| CN113264926A (en) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | Co-crystal of vitexin and reserpine and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1919206A (en) | Vitexin injection and oral administration preparation thereof | |
| CN1706397A (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN1555807A (en) | Stability enhanced erigeron breviscapus injection and its preparation method | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1287808C (en) | Ginkgo leaf extract composition | |
| CN1481806A (en) | Injection formulation of astragalus root saponin and its preparation mehod | |
| CN1425379A (en) | Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method | |
| CN1425430A (en) | Traditional Chinese medicine active part composition for curing cardio and cerebral vascular disease and its preparing method | |
| CN1810269A (en) | Freeze dried perhexiline powder for injection and its prepn process | |
| CN1729989A (en) | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method | |
| CN1679831A (en) | Oral medicine for cardio-cerebral blood vessel diseases and its making method | |
| CN1915273A (en) | Medicinal composition, preparation method and quality control method | |
| CN1594315A (en) | Novel process for preparation of silybum mariamum extractive methylglucamine | |
| CN1602919A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1660284A (en) | Compound preparation of notoginseng and safflower for treating cardiovascular and cerebrovascular diseases | |
| CN1915256A (en) | Medicinal composition, preparation method and quality control method | |
| CN1868500A (en) | Medicine composition contg. tetramethylpyrazine, prepn. method and use thereof | |
| CN1915295A (en) | Medicinal composition, preparation method and quality control method | |
| CN1927350A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1634254A (en) | Compound formulation of astragalus root for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1915293A (en) | Medicinal composition, preparation method and quality control method | |
| CN1915255A (en) | Medicinal composition, preparation method and quality control method | |
| CN1460478A (en) | Huangyangning slow-releasing preparation | |
| CN1927320A (en) | Traditional Chinese medicine composition for treating speckle | |
| CN1915294A (en) | Medicinal composition, preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070228 |